Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety

International Journal of Clinical Practice

Volumn 56, Issue 6, 2002, Pages 434-439

  Wan, G J ^a   Crown, W H ^a   Berndt, E R ^a   Finkelstein, S N ^a   Ling, D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG FORMULATION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANXIETY; CYCLOHEXANOLS; DATABASES, FACTUAL; DEPRESSION; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HOSPITAL COSTS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 0036332285     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
2. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey
3. Comorbid depression and anxiety spectrum disorders
4. The societal costs of chronic major depression
5. The under-recognition and under-treatment of depression: What is the breadth and depth of the problem?
6. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey
7. Health economics and cost implications of anxiety and other mental disorders in the United States
8. The economic burden of depression in 1990
9. The economic burden of anxiety disorders in the 1990s
10. Cost of anxiety disorders: Impact of comorbidity
11. Health and disability costs of depressive illness in a major US corporation
12. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates
13. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary
14. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
15. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression
16. SSRIs and SNRIs: Broad spectrum of efficacy beyond major depression
17. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
18. Depression in managed care: Costs of selective serotonin reuptake inhibitors
19. Variation in treatment compliance and costs by antidepressant class: Analysis in an HMO setting
20. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy: Following selective serotonin reuptake inhibitor therapy for depression
21. One-year costs of secondline therapies for depression
22. Long-term costs of treatment for depression: Impact of drug selection and guideline adherence
23. A psychiatric patient classification system: An alternative to diagnosis-related groups
24. Retrospective analysis of the health care costs of bupropion sustained release in comparison with other antidepressants
25. Managing depression in medical outpatients
26. Overview of patient compliance with medication dosing: A literature review
27. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence
28. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program
29. Predictors of a medical-offset effect among patients receiving antidepressant therapy
30. An examination of the relationship between non-depression-related costs and uninterrupted Tx
31. Antidepressant selection for major depressive disorder: The budgetary impact on managed care
32. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders
33. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder
34. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom
35. A pharmacoeconomic evaluation of major depressive disorder
36. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs
37. The health economic impact of antidepressant usage from a payer's perspective: A multinational study
38. Cost-effectiveness of venlafaxine XR compared with diazepam in the treatment of generalized anxiety disorder in the UK
39. Evolution of remission as the new standard in the treatment of depression
40. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
41. Recovery from depression, work productivity, and health care costs among primary care patients